History

2019 - 2018

  • Y2019 IND of AL101-OME for phase 2A has been summited

  • Y2019 IND of AL101-NASH for phase 2A has been summited

  • Y2019 MOU on PASylation with XL-protein was signed

  • Y2018 Phase 2 clinical trials for AL101-AMD have been started

  • Y2018 Approval from KFDA on the revised IND for Phase 2 clinical trial of AL101-AMD was given

  • Y2018 Sales for Ob-X have been launched at home-shopping channels

2010-2017

  • Y2016 Listed in KONEX

  • Y2013 ~ Y2016 12 billion won was totally raised from venture capital firms

  • Y2015 Approval from KFDA on the IND of Phase 2 clinical trial of AL101-AMD for wet AMD was given

  • Y2013 Approval from KFDA on the IND of Phase 3 clinical trial of AL101-AOB for abdominal obesity was given

  • Y2012 Sales of Ob-X have begun

  • Y2010 Ob-X has been approved from KFDA as a specific health functional food with proven claims of visceral fat reduction

2004-2009

  • Y2009 Completed Phase 2 clinical trial of AL101-AOB for abdominal obesity

  • Y2007 Awarded INNO-BIZ certification from SMBA

  • Y2006 Attracted capital from KDB for technology development

  • Y2005 Selected as 'Excellent Company' from Korea Technology and Credit Guarantee agency

  • Y2004 ~ Y2009 Awarded numerous research grants from the Ministry of Health & Welfare and SMBA for developing new drugs

1999-2003

  • Y2000 Research center was certified

  • Y1999 Recognized as a start-up with good technology